Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting (2016)
- Authors:
- USP affiliated authors: HOFF, PAULO MARCELO GEHM - FM ; MANO, MAX SENNA - FM
- Unidade: FM
- DOI: 10.1007/s12282-014-0564-9
- Subjects: NEOPLASIAS MAMÁRIAS; ANTINEOPLÁSICOS; EVENTO ADVERSO A MEDICAMENTO; BRASIL
- Language: Inglês
- Imprenta:
- Source:
- Título: Breast cancer
- ISSN: 1340-6868
- Volume/Número/Paginação/Ano: v. 23, n. 2, p. 261-265, 2016
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
SANTANA, Iuri A. et al. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, v. 23, n. 2, p. 261-265, 2016Tradução . . Disponível em: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9. Acesso em: 03 jan. 2026. -
APA
Santana, I. A., Oliveira, J. A., Lima, J. M. da S., Testa, L., Piato, J. R. M., Hoff, P. M., & Mano, M. S. (2016). Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting. Breast cancer, 23( 2), 261-265. doi:10.1007/s12282-014-0564-9 -
NLM
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2026 jan. 03 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9 -
Vancouver
Santana IA, Oliveira JA, Lima JM da S, Testa L, Piato JRM, Hoff PM, Mano MS. Feasibility of two schedules of weekly paclitaxel in HER2-negative early breast cancer in a Brazilian community setting [Internet]. Breast cancer. 2016 ; 23( 2): 261-265.[citado 2026 jan. 03 ] Available from: http://link.springer.com/article/10.1007%2Fs12282-014-0564-9 - Malignancy-related hypercalcemia in the bishosphonate era
- Rare tumors research in emerging countries
- Ascite quilosa em paciente com carcinoma ductal invasivo de mama
- Metronomic chemotherapy in the neoadjuvant setting: results of two parallel feasibility trials (TraQme and TAME) in patients with HER2+ and HER2− locally advanced breast cancer
- Câncer de mama HER2 positivo: tratamento (NEO) adjuvante - análise das pacientes tratadas no ICESP
- Serum levels of VEGF and MCSF in HER2+/HER2- breast cancer patients with metronomic neoadjuvant chemotherapy
- Carcinoma neuroendócrino primário de mama (CNEM) - um diagnóstico raro: relato de dois casos
- Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial
- Value of systemic staging in asymptomatic early breast cancer
- Phase 3, randomized, double-blind, placebo-controlled multicenter trial of daily everolimus plus weekly trastuzumab and paclitaxel as first-line therapy in women with HER2+ advanced breast cancer: BOLERO-1
Informações sobre o DOI: 10.1007/s12282-014-0564-9 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
